The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1500-1507

  Imboden, Michael ^a   Murphy, Kristopher R ^a   Rakhmilevich, Alexander L ^a   Neal, Zane C ^a   Xiang, Rong ^b   Reisfeld, Ralph A ^b   Gillies, Stephen D ^c   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Lexigen Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYBRID PROTEIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN; PROTEIN HUKS1 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; H-2 ANTIGENS; IMMUNOCONJUGATES; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SPLEEN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035866345     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
2. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity
3. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow
4. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
5. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy
6. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes
7. In search of the 'missing self': MHC molecules and NK cell recognition
8. NK cell receptors
9. Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells
10. Relationship between antibody-dependent cell-mediated cytotoxicity due to anti-HTLV-1 and negative signal of major histocompatibility complex class I antigens on adult T-cell leukemia cell lines
11. Protective effects of interferon-γ on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells
12. Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties
13. Recognition of class 1 major histocompatibility complex molecules by Ly-49: Specificities and domain interactions
14. Cloning and characterization of 5E6(Ly-49C), a receptor molecule expressed on a subset of murine natural killer cells
15. Recognition of class 1 MHC by NK receptor Ly-49C: Identification of critical residues
16. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells
17. Expression of anti-tetanus toxoid antibody in transfected murine melanoma cells
18. Accurate identification of experimental pulmonary metastases
19. Calculation of lytic units for the expression of cell-mediated cytotoxicity
20. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors
21. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice
22. Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins
23. T cell memory against colon carcinoma is long-lived in the absence of antigen
24. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
25. Altered MHC class I antigens in tumors
26. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells
27. Cloning and functional characteristics of murine large granular lymphocyte-1: A member of the Ly-49 gene family (Ly-49G2)
28. Human leukocyte antigen class I expression on squamous cell carcinoma cells regulates natural killer cell activity
29. Heterogeneity among Ly-49C natural killer (NK) cells: Characterization of highly related receptors with differing functions and expression patterns
30. Impaired MHC class I (H-2Dd)-mediated protection against Ly-49A+ NK cells after amino acid substitutions in the antigen binding cleft
31. Improved efficacy of mouse antibody-cytokine fusion proteins in syngeneic mouse tumor models is due to their reduced immunogenicity
32. Markedly decreased expression of TAPI and LMP2 genes in HLA class I-deficient human tumor cell lines
33. Relationship between myc oncogene activation and MHC class I expression
34. Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function
35. Histocompatibility antigens on murine tumors
36. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis
37. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2
38. Acute immunologic effects of interleukin-2 therapy in cancer patients: Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens
39. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2
40. Activation of multiple effector mechanisms to enhance tumor immunotherapy
41. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro